Explore

Trendline Trendline
DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2026 in New York

DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2026 in New York

DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2026 in New York
Rapid Read Rapid Read
Aalto University Develops Laser Heat Treatment to Combat Age-Related Macular Degeneration

Aalto University Develops Laser Heat Treatment to Combat Age-Related Macular Degeneration

Researchers at Aalto University have developed a new laser heat treatment aimed at combating the dry form of age-related macular degeneration (AMD), a condition affecting millions of Americans over 40. The treatment involves using near-infrared light to gently warm the tissue at the back of the eye, activating natural repair systems without causing harm. This approach targets the early stages of AMD, aiming to strengthen the protective mechanisms inside eye cells before significant damage occurs. The method has shown promise in animal studies, and human trials are set to begin in Finland in 2026 to assess safety and efficacy.
Trendline Trendline
Nielsen BioSciences Completes Successful Phase 3 Trial for CANDIN in Wart Treatment

Nielsen BioSciences Completes Successful Phase 3 Trial for CANDIN in Wart Treatment

Nielsen BioSciences Completes Successful Phase 3 Trial for CANDIN in Wart Treatment
Rapid Read Rapid Read
FDA Approves Brenus Pharma's IND Application for STC-1010 in Metastatic Colorectal Cancer

FDA Approves Brenus Pharma's IND Application for STC-1010 in Metastatic Colorectal Cancer

Brenus Pharma, a biotechnology company specializing in immuno-oncology, has received approval from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for STC-1010. This drug is designed to treat microsatellite stable (MSS) metastatic colorectal cancer (mCRC), a condition affecting approximately 95% of mCRC patients who typically show minimal response to standard immunotherapies. The FDA's approval allows Brenus Pharma to proceed with clinical evaluations in the U.S. under the BreAK-CRC001 study. This development follows European regulatory approvals and initial positive results from early Phase Ia trials. The company plans to present further data at the ESMO annual congress in 2026.
Trendline Trendline
Veradermics to Present Phase 2/3 Study Results of VDPHL01 for Pattern Hair Loss at World Congress

Veradermics to Present Phase 2/3 Study Results of VDPHL01 for Pattern Hair Loss at World Congress

Veradermics to Present Phase 2/3 Study Results of VDPHL01 for Pattern Hair Loss at World Congress
Rapid Read Rapid Read
New Laser Heat Treatment Aims to Prevent Blindness in AMD Patients

New Laser Heat Treatment Aims to Prevent Blindness in AMD Patients

Researchers at Aalto University have developed a new laser heat treatment that could potentially prevent blindness caused by age-related macular degeneration (AMD). This condition affects a significant number of older adults, with around one-third of people over 80 and about 20 million Americans aged 40 and older living with it. The majority of AMD cases are of the dry form, which progresses gradually and can severely damage central vision. The new approach involves using controlled heat delivered with near-infrared light to activate natural repair systems in the eye's cells before severe damage occurs. This method aims to strengthen the protective mechanisms inside affected cells, which weaken with age, leading to oxidative stress and the accumulation of fatty protein deposits known as drusen. These deposits are a major warning sign of dry AMD and can interfere with the retina's health.
Trendline Trendline
Brenus Pharma's Immunotherapy for Colorectal Cancer Receives FDA IND Approval

Brenus Pharma's Immunotherapy for Colorectal Cancer Receives FDA IND Approval

Brenus Pharma's Immunotherapy for Colorectal Cancer Receives FDA IND Approval
Trendline Trendline
Crystalys Therapeutics Initiates Phase 2 Trial for Gout Treatment with Dotinurad

Crystalys Therapeutics Initiates Phase 2 Trial for Gout Treatment with Dotinurad

Crystalys Therapeutics Initiates Phase 2 Trial for Gout Treatment with Dotinurad
Rapid Read Rapid Read
Eli Lilly's VERVE-102 Shows Promising Results in Reducing Cholesterol

Eli Lilly's VERVE-102 Shows Promising Results in Reducing Cholesterol

Eli Lilly and Company announced positive results from the Phase 1b Heart-2 study of VERVE-102, an investigational in vivo base editing medicine. The study demonstrated that a single intravenous infusion of VERVE-102 significantly reduced PCSK9 and LDL-C levels in participants with heterozygous familial hypercholesterolemia (HeFH) or premature coronary artery disease (CAD). The reductions were dose-dependent and sustained over an 18-month follow-up period. VERVE-102 aims to mimic the protective effects of naturally occurring PCSK9 variants, offering a potential one-time treatment for hypercholesterolemia.
Trendline Trendline
Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference in New York

Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference in New York

Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference in New York
Trendline Trendline
Nielsen BioSciences Reports Successful Phase 3 Trial of CANDIN for Wart Treatment

Nielsen BioSciences Reports Successful Phase 3 Trial of CANDIN for Wart Treatment

Nielsen BioSciences Reports Successful Phase 3 Trial of CANDIN for Wart Treatment
Trendline Trendline
Forlong Completes Phase I Trials of FL115 for Advanced Solid Tumors with Promising Results

Forlong Completes Phase I Trials of FL115 for Advanced Solid Tumors with Promising Results

Forlong Completes Phase I Trials of FL115 for Advanced Solid Tumors with Promising Results